In-depth analysis of the efficacy and price of Pemigatinib: from the latest hot spots to patient concerns

1. Introduction of hot spots: focus on new drugs for hepatobiliary tumors

In recent years, the field of targeted tumor therapy has continued to expand, especially in the field of rare but highly malignant tumors such as cholangiocarcinoma (Cholangiocarcinoma). In 2024, at the American Society of Clinical Oncology (ASCO) meeting, targeted therapy data for FGFR2 fusion or rearrangement-positive advanced cholangiocarcinoma once again became the focus of academic attention. Among them, pemigatinib (Pemigatinib) is the first oral targeted drug approved by the FDA for FGFR2 gene abnormalities, and is called "new hope for patients with cholangiocarcinoma."

Just this year, a number of real-world studies have been published at home and abroad, showing that pemetinib has good efficacy and tolerability in different lines of treatment. As more and more patients and doctors come into contact with this new drug, its efficacy and price have gradually become hot topics of discussion among patient groups.

This article will systematically analyze the clinical efficacy and indication expansion progress of pemetinib, and combine it with price comparisons at home and abroad to help patients fully understand this drug.

2. What is pemetinib? Analysis of mechanism of action

Pemigatinib (Pemigatinib) is an oral small molecule selective FGFR inhibitor whose main target ToFGFR1, FGFR2 and FGFR3.

1.Target mechanism: FGFRGene mutations or fusion rearrangements can lead to abnormal activation of cell signaling pathways and promote the occurrence and development of tumors. Pemetinib inhibits the growth and spread of cancer cells by inhibiting the phosphorylation process of FGFR and blocking its downstream signaling pathways.

2.Approval progress: 2020 year, FDAPemetinib was first approved for the treatment of patients with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements who have received at least one prior systemic therapy. This is the first FGFR targeted drug in the field of cholangiocarcinoma.

3.Research expansion: Currently, pemetinib is also exploring the possibility of being used in myelodysplastic syndrome (MDS), urothelial cancer and other diseases, showing broader clinical prospects.

3. Clinical efficacy of pemetinib

Pemetinib has shown strong efficacy in multiple international clinical studies.

1.FIGHT-202Study (pivotal trial)

Eligible subjects:FGFR2Patients with cholangiocarcinoma who are positive for fusion or rearrangement

Key results:

Objective response rate (ORR): 36%

Disease control rate (DCR): 82%

Median progression-free survival (PFS): 6.9months

Median overall survival (OS): 21.1months

Conclusion: Compared with traditional chemotherapy (ORRinsufficient10%), pemetinib significantly improved the response rate and survival of patients.

2.Real world applications

Multi-center clinical practice at home and abroad has shown that even in second-line or third-line treatment, pemetinib can still bring lasting relief to some patients.

Some patients even experienced significant tumor shrinkage, significant improvement in symptoms, and improved quality of life after taking the drug.

3.Security

Common side effects include hyperphosphatemia, oral ulcers, nail changes, rash, and mild to moderate gastrointestinal reactions.

Most adverse events are controllable and reversible and will not lead to serious discontinuation of treatment.

4. Price differences and purchasing channels at home and abroad

Although the efficacy is promising, price is always the practical issue that patients are most concerned about.

1.Domestic market situation

Pemetinib has been launched in China, named “Pemetinib Tablets”.

It has not been included in the medical insurance catalog yet, so patients need to purchase it at their own expense.

Common specifications on the market:

4.5mg × 14tablets

9mg × 14tablets

Domestic price range: 210,000 – 510,000 yuan/ boxes (slightly different due to different specifications and channels).

2.Overseas market conditions

In the United States and Europe, the common specifications are 13.5mg × 14 tablets.

Price: Approximately 7RMB / box (price fluctuates with exchange rate).

3.Generic drug selection

Take the generic version produced by Laos Lucius Pharmaceuticals (Lucius) as an example:

Specifications:4.5mg × 14tablets

Price: 700around / box (approximately 1/30 of the original drug).

The ingredients of generic drugs are basically the same as the original drugs, but due to the lack of large-scale clinical verification, patients need to be cautious when choosing, and it is recommended to use them under the guidance of professional doctors.

5. Why is the price difference so huge?

1. Research and development costs: Original drugs require a research and development cycle of more than ten years and hundreds of millions of dollars of investment, so the initial pricing on the market is generally high.

2. Medical insurance access: Domestic medicines are not covered by medical insurance, which means patients pay the full amount out of pocket, while some imported drugs are covered by insurance in the United States or the European Union.

3. Differences in generic drug policies: Some countries have relaxed patent protection and allowed generic drugs to be put on the market, leading to a sharp drop in prices.

6. Pemetinib’s domestic prospects and hot trends

1.There is a strong call for medical insurance access

As more patients with cholangiocarcinoma use pemetinib, patient groups and medical circles generally call for its inclusion in medical insurance as soon as possible to reduce the financial burden on patients.

2.Indications expansion

Multiple clinical trials have shown that pemetinib is promising for:

FGFRMutation-associated urothelial carcinoma

Some hematological tumors

Bone cancer and other solid tumors

3. Exploration in combination with immunotherapy

The latest research is trying to combine pemetinib with PD-1/PD-L1 immune checkpoint inhibitors, hoping to further improve the efficacy of patients with cholangiocarcinoma.

7. Summary of issues that patients are most concerned about

1. Is the efficacy better than chemotherapy?

——Yes, clinical data show that the objective response rate of pemetinib (36%) is much higher than that of traditional chemotherapy (less than 10%).

2.Will prices drop?

——If it is included in medical insurance in the future, it is expected that the actual out-of-pocket proportion of patients will be significantly reduced; although the price of overseas generic drugs is low, attention must be paid to the formality of the channels and the safety of medication.

3.How long does it take to take effect?

——Most patients can observe tumor shrinkage or stable disease within 2–3 cycles (about 2–3 months).

4.Is it suitable for all patients with cholangiocarcinoma?

——Only applicable to patients who are positive for FGFR2 fusion or rearrangement and need to be confirmed by genetic testing.

Pemetinib, as the world's first approved FGFR inhibitor, fills the gap in precision treatment of cholangiocarcinoma and provides patients with a new treatment option. Although it is currently expensive and not covered by medical insurance, its outstanding efficacy and controllable safety make it a targeted drug of great concern to the patient community. With future medical insurance negotiations, localization progress and the development of generic drugs, the accessibility of pemetinib is expected to gradually increase.

For patients, timely genetic testing is required to confirm whether there is FGFR2 fusion or rearrangement to determine whether pemetinib is suitable. Clinicians’ professional guidance and standardized treatment plans are also crucial.

xa0

References

1."New England Journal of Medicine":Pemigatinib in Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma (FIGHT-202 Trial)

2.FDAOfficial website: FDA approves pemigatinib for cholangiocarcinoma with an FGFR2 fusion or rearrangement

3.ASCO 2024Conference abstracts and related reports